Perfil
David A.
Karlin was Senior Vice President of Clinical Development and Regulatory Affairs of Poniard Pharmaceuticals, Inc. since July 2005 to November 2008.
He was Vice President of Clinical Research for Cellegy Pharmaceuticals, Inc. from 2002 to 2005 and Vice President of Clinical Development for Genteric, Inc. Dr. Karlin was Senior Medical Director of Matric Pharmaceuticals, Inc. from 1991 to 2001, Vice President for Clinical Research and Medical Director of SciClone Pharmaceuticals, Inc. from 1995 to 1999.
He was Director of Medical Research for Syntex Corporation from 1986 to 1995 and an Associate Professor at the Temple University School of Medicine, the University of Texas M.D.
Anderson Hospital and the Tumor Institute.
Dr. Karlin received an MD from the University of Chicago and a BS degree in Biology from the University of Illinois.
Antiguos cargos conocidos de David A. Karlin.
| Empresas | Cargo | Fin |
|---|---|---|
Cellegy Pharmaceuticals, Inc.
 Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Director Técnico/Científico/I+D | 22/04/2009 |
| PONIARD PHARMACEUTICALS, INC. | Consejero General | 21/11/2008 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Cellegy Pharmaceuticals, Inc.
Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Health Technology |
- Bolsa de valores
- Insiders
- David A. Karlin
